Nantahala Capital Management LLC Takes Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Nantahala Capital Management LLC bought a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 100,000 shares of the company's stock, valued at approximately $1,390,000. Nantahala Capital Management LLC owned 0.20% of Tyra Biosciences at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in Tyra Biosciences in the fourth quarter valued at approximately $31,000. US Bancorp DE bought a new position in shares of Tyra Biosciences in the 4th quarter worth $50,000. Aquatic Capital Management LLC acquired a new stake in Tyra Biosciences in the 4th quarter valued at $64,000. Wells Fargo & Company MN increased its stake in Tyra Biosciences by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after purchasing an additional 3,236 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Tyra Biosciences by 130,587.5% during the fourth quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company's stock worth $145,000 after buying an additional 10,447 shares during the last quarter. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Trading Up 3.6 %

Shares of TYRA stock traded up $0.38 during trading on Friday, hitting $10.86. The company's stock had a trading volume of 394,236 shares, compared to its average volume of 253,816. The company has a market cap of $576.56 million, a PE ratio of -6.75 and a beta of 1.19. The business has a fifty day moving average of $9.80 and a 200-day moving average of $13.90. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05. As a group, research analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on TYRA shares. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. UBS Group initiated coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a "buy" rating and a $28.00 price objective for the company. Finally, Wedbush restated an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences has a consensus rating of "Buy" and an average price target of $30.83.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the transaction, the director now owns 443,885 shares in the company, valued at approximately $6,107,857.60. This represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 15.40% of the company's stock.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.